Clopidogrel
Product Images NDC 64205-357

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 64205-357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Readymeds, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A dot plot chart titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs).' It shows the effect of various PPIs (dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, omeprazole 80 mg) on active metabolite AUC relative to clopidogrel bisulfate alone, with mean values and 90% confidence intervals.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rates (%) over 12 months of follow-up. It compares two groups: Placebo (+ aspirin) and Clopidogrel Bisulfate (+ aspirin), with event rates increasing over time for both groups. The graph includes a p-value indicating statistical significance.*

FDA Label Image

Figure 3 (Clopidogrel Fig3)

A hazard ratio forest plot from the CURE study showing patient baseline characteristics and on-study concomitant medications comparing Clopidogrel Bisulfate plus aspirin versus placebo plus aspirin. The chart illustrates hazard ratios with confidence intervals across variables like age, gender, race, cardiac enzymes, prior medical events, and various medications or therapies.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study* (Clopidogrel Fig4)

A Kaplan-Meier cumulative event rate graph showing death rates over 28 days in the COMMIT study for Clopidogrel versus placebo. The y-axis represents the percentage of deaths before first discharge, and the x-axis shows days since randomization, with a proportional risk reduction of 7% (p=0.03) favoring Clopidogrel. The graph notes all patients received aspirin.*

FDA Label Image

Figure 5 (Clopidogrel Fig5)

A cumulative event rate graph showing the combined endpoint of re-infarction, stroke, or death in the COMMIT Study over 28 days. The vertical axis represents percentage with events, and the horizontal axis shows days since randomization. Two lines compare placebo and Clopidogrel, with event percentages of 10.1% and 9.2%, respectively, indicating a 9% proportional risk reduction for Clopidogrel.*

FDA Label Image

Figure 6 (Clopidogrel Fig6)

A forest plot chart titled 'Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study.' It displays odds ratios with 95% confidence intervals comparing Clopidogrel and placebo groups across various baseline categories, including sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent given, prognostic index, and metoprolol allocation. The plot includes event counts and percentages for each subgroup, with a proportional reduction marker and p-values indicating heterogeneity and treatment effect significance.*

FDA Label Image

Figure 7: Effects Of Adding Clopidogrel Bisulfate To Aspirin In The Non-prespecified Subgroups In The Commit Study (Clopidogrel Fig7)

A forest plot chart illustrating the effects of adding clopidogrel bisulfate to aspirin in non-prespecified subgroups from the COMMIT study. It compares event percentages between clopidogrel (n=22,961) and placebo (n=22,891) groups across Killip class, previous MI, and infarct location categories. Odds ratios with confidence intervals are shown, indicating proportional risk reduction. A global heterogeneity test is also included.*

FDA Label Image

Figure 8: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig8)

A line graph depicting cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up in the CAPRIE study. It compares two treatments, Aspirin and Clopidogrel Bisulfate, showing event rates increasing over time for both. The graph includes a p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel hydrogen sulfate, showing molecular bonds and atom labeling, including sulfur, chlorine, and ester groups, representing the active ingredient Clopidogrel.*

FDA Label Image

Photo (Photo)

Packaging label for ReadyMeds Clopidogrel 75 mg tablets. The label displays the proprietary name, strength of 75 mg, a quantity of 30 tablets, NDC number 64205-357-30, and placeholders for expiration date and lot number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.